AG 7352 Hydrochloride
- Product Name
- AG 7352 Hydrochloride
- CAS No.
- 175519-16-1
- Chemical Name
- AG 7352 Hydrochloride
- Synonyms
- SNS-595 Hydrochloride;AG 7352 Hydrochloride;Voreloxin (SNS-595) HCl;Vosaroxin Hydrochloride;Voreloxin (Hydrochloride);Vosaroxin hydrochloride salt;Voreloxin 13C-D3 Hydrochloride;Voreloxin(SNS-595)hydrochloride;Vosaroxin hydrochloride >=98% (HPLC);Voreloxin Impurity 1 (Hydrochloride)
- CBNumber
- CB52645152
- Molecular Formula
- C18H20ClN5O4S
- Formula Weight
- 437.9
- MOL File
- 175519-16-1.mol
AG 7352 Hydrochloride Property
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- color
- White to gray
- optical activity
- [α]/D +42 to +52°, c =1 in 0.1 M NaOH
- Water Solubility
- H2O: 1mg/mL, clear (warmed)
N-Bromosuccinimide Price
- Product number
- CS-0927
- Product name
- VoreloxinHydrochloride
- Purity
- 99.96%
- Packaging
- 5mg
- Price
- $120
- Updated
- 2021/12/16
- Product number
- CS-0927
- Product name
- VoreloxinHydrochloride
- Purity
- 99.96%
- Packaging
- 10mg
- Price
- $210
- Updated
- 2021/12/16
- Product number
- A3925
- Product name
- VoreloxinHydrochloride
- Packaging
- 5mg
- Price
- $221
- Updated
- 2021/12/16
- Product number
- A3925
- Product name
- VoreloxinHydrochloride
- Packaging
- 10mg
- Price
- $378
- Updated
- 2021/12/16
- Product number
- CS-0927
- Product name
- VoreloxinHydrochloride
- Purity
- 99.96%
- Packaging
- 50mg
- Price
- $750
- Updated
- 2021/12/16
AG 7352 Hydrochloride Chemical Properties,Usage,Production
Uses
Voreloxin Hydrochloride is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.
Biological Activity
Voreloxin hydrochloride (SNS-595, Vosaroxin) is a potent Topoisomerase II inhibitor with broad-spectrum antitumor activity. Phase 2.
in vivo
Voreloxin (20 mg/kg, i.v.) alone results in 80% reduction in bone marrow cellularity of CD-1 mice by administration one dose every 4 days repeated twice (q4d ×2). voreloxin at 10 mg/kg in combination with cytarabine causes ablation of the marrow, dilation of sinusoids, and infiltration of adipocytes in mice. Voreloxin (20 mg/kg, i.v.) combined with cytarabine causes a reversible decrease in myeloid and lymphoid cells in bone marrow and peripheral blood CD-1 mice. voreloxin (10 mg/kg, q4d ×2) and cytarabine in combination causes reversible neutropenia with a more modest impact on platelets CD-1 mice[2].
target
| Target | Value |
| Topo II |
IC 50
Topoisomerase II
References
[1] Hotinski AK, et al. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother. 2015 Jun;16(9):1395-402. DOI:10.1517/14656566.2015.1044437
[2] Scatena CD, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8. DOI:10.1007/s00280-009-1234-z
[3] Walsby EJ, et al. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 2011 Mar;96(3):393-9. DOI:10.3324/haematol.2010.032680